

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Lutetium-177 DOTATATE for treating unresectable, somatostatin receptor-positive non-progressive gastroenteropancreatic neuroendocrine tumours [ID857]

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Imaging Equipment (lutetium-177 DOTATATE) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action Radiotherapy • Beating Bowel Cancer • Black Health Agency • Bowel Cancer Information • Bowel Cancer UK • Cancer Black Care • Cancer Equality • Cancer 52 • HAWC • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Macmillan Cancer Support • Maggie's Centres • Marie Curie Cancer Care • Muslim Council of Britain • Pancreatic Cancer Action • Pancreatic Cancer UK • PLANETS Charity • Rarer Cancers Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care • The NET Patient Foundation <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • Association of Coloproctology of Great Britain • Bladder and Bowel Foundation • British Geriatrics Society • British Institute of Radiology • British Nuclear Medicine Society • British Society of Gastroenterology • British Psychosocial Oncology Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • Hospira UK (5-fluorouracil, octreotide) • Ipsen (lanreotide) • Novartis Pharmaceuticals UK (octreotide long acting release) • Sun Pharmaceuticals UK (octreotide) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Bowel & Cancer Research • Cochrane Colorectal Cancer Group • Cochrane Metabolic and Endocrine Disorders Group • Cochrane Upper Gastrointestinal and Pancreatic Diseases Group • CORE – Digestive Disorders Foundation • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research • Pancreatic Cancer Research Fund

National Institute for Health and Care Excellence

Matrix for the technology appraisal of lutetium-177 DOTATATE for treating unresectable, somatostatin receptor-positive non-progressive gastroenteropancreatic neuroendocrine tumours

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Cancer Research UK • CRUK, ECMC and UK Radiopharmacy Group Taskforce (CERT) • Internal Dosimetry Users Group (IDUG) • Institute of Physics and Engineering Medicine • National Pharmacy Association • Pancreatic Cancer Action • Pancreatic Society of Great Britain and Ireland • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiographers • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • Society of Endocrinology • UK Clinical Pharmacy Association • UK Endocrine Pathology Society (UKEPS) • UK Health Forum • UK and Ireland Neuroendocrine Tumour Society (UKI NETS) • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Harrow CCG • NHS Redbridge CCG • Welsh Government 	<p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.